Hyperpigmentation News and Research

RSS

Hyperpigmentation is one of the most common pigmentation problems in darker-skinned individuals is hyperpigmentation (or the darkening of the skin). Usually the result of some type of inflammation or injury to the skin, such as a cut, burn or scrape, hyperpigmentation produces darkened areas of the skin that can last months or years. Even healed acne lesions can leave permanent dark spots in darker-skinned people that, in some cases, can be more distressing than the original acne.

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).

28 Jul 2011

Adoption of premium-priced sclerotherapy agents will contribute to growth of US sclerotherapy market

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States sclerotherapy market will experience rapid procedural growth stemming from favorable patient demographics and increased patient demand. Polidocanol, a sclerosing agent used to chemically treat varicose and spider veins, received FDA approval in 2010 and is expected to show significant growth in the US.

8 Jun 2011

Obagi Medical Products prices secondary offering

Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, today announced the pricing of the secondary public offering of 2,690,244 shares of its common stock by the Stonington Capital Appreciation 1994 Fund, L.P. and the Zein and Samar Obagi Family Trust, at a public offering price of $10.25 per share.

20 Nov 2010

Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 16th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Paris, France from November 11 to 13, 2010.

12 Nov 2010

Kiehl's to introduce Photo-Age Corrector for treating UV damage on skin

With Labor Day fast-approaching and the summer sun almost a thing of the past, women and men across the United States will be in search of fall's must-have skin renewal system to repair and reverse UV damage.

27 Aug 2010

Dermatologist discusses treatment for acne and melasma

The U.S. Census Bureau predicts that the Asian-American population will total 40 million people by 2050. While as a whole this group is characterized by very dark hair and dark eyes, there is much diversity in Asian skin tones – from very light, pale skin to light or dark brown skin. One common thread is the pigmentation issues that Asian Americans often face as after-effects of other dermatologic problems that can be as troublesome as the original condition itself.

6 Aug 2010

Collagen Induction Therapy and Ultrasonic Microdermabrasion demonstrations at Lecada's open house

An open house on Thursday, June 17th, celebrated Lecada Medical Artistry's grand opening at 3710 West Azeele Street, Tampa. Lecada offers innovative treatments for face and body that provide aesthetic and anti-aging solutions designed to help you look and feel your best.

14 Jul 2010

Vitamins touted in skin care products reduce signs of sun-damaged skin: Study

While everyone knows that getting an adequate daily dose of vitamins and minerals is important in maintaining one's overall health, many question whether or not the vitamins touted in skin care products work in reducing the signs of sun-damaged skin.

13 Apr 2010

Envy Medical launches new Lumixyl Brightening System for treating hyperpigmentation

Envy Medical, Inc., introduces the new Lumixyl™ Brightening System, a revolutionary multi-faceted approach to effectively treat hyperpigmentation without irritation or other side effects associated with prescription Hydroquinone or retinoids. This professional skincare system introduction builds on the success of the Lumixyl Topical Brightening Creme introduced in 2009.

9 Mar 2010

People with skin of color more prone to dermatologic problems than those with lighter skin tones

According to projections from the United States Census Bureau, people with skin of color will comprise approximately half of the U.S. population by 2050. This group, which includes African-Americans, Asians, Latinos and other ethnicities, are more prone to certain dermatologic problems than those with lighter skin tones due to their genetic make-up and in some cases cultural practices.

5 Mar 2010

Revance Therapeutics closes $35 million Series D financing

Revance Therapeutics, Inc. (“Revance”) today announced the first $25 million closing of a $35 million Series D financing. The round was led by Essex Woodlands Health Ventures Fund VIII.

4 Jan 2010

SkinMedica enters into a global license agreement with New York University

SkinMedica, Inc. and New York University announced today that they have entered into a global license agreement to develop novel products to address skin hyperpigmentation based on technology invented at NYU.

27 Oct 2009

Findings provide new insight on skin pigmentation

The skin's pigment cells can be formed from completely different cells than has hitherto been thought, a new study from the Swedish medical university Karolinska Institutet shows. The results, which are published in the journal Cell, also mean the discovery of a new kind of stem cell.

19 Oct 2009

FDA undecided on safety guidelines for hydroquinone use

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the US market for physician-dispensed cosmeceutical pigment control products will experience considerable growth in sales over the next five years. MRG's US Markets for Physician-Dispensed Cosmeceuticals 2009 report finds, however, that product safety issues involving hydroquinone, the active ingredient in many pigment control products, have led the Food and Drug Administration (FDA) to second guess the use of the compound in such products.

8 Sep 2009

Topical fluorouracil may improve appearance of aging skin

Topical application of the chemotherapy medication fluorouracil appears to reduce potentially precancerous skin patches and improve the appearance of sun-damaged skin, according to a report in the June issue of Archives of Dermatology.

16 Jun 2009

Laser technology shown to effectively clear acne

From the removal of childhood birthmarks to skin rejuvenation, laser technology has become a mainstay in dermatology.

5 Mar 2009

Enhanced skin cancer risk linked to defects in cellular aging controls

Cell lifespan is limited by telomeres, DNA sequences that cap chromosomes and control the number of times a cell may be copied.

23 Feb 2009

Higher death rates in kidney patients with nephrogenic systemic fibrosis

Nephrogenic systemic fibrosis (NSF) is a newly identified debilitating and painful condition that affects patients with kidney failure and is characterized by a thickening and hardening of the skin.

29 Sep 2007

Skin cooling may increase risk of discoloration after laser treatment

A cooling technique intended to protect the skin may actually increase the risk of discoloration in dark-skinned patients undergoing laser treatments for mole-like skin lesions, according to a report in the September issue of Archives of Dermatology, one of the JAMA/Archives journals.

18 Sep 2007

Intensity modulated radiation therapy reduces breast cancer treatment side effects

Women with early stage breast cancer who receive a newer type of radiation called intensity modulated radiation therapy (IMRT) develop significantly fewer side effects than women who receive traditional radiation therapy, according to a study released in the August 1 edition of the International Journal of Radiation Oncology * Biology * Physics, the official journal of ASTRO.

1 Aug 2007